期刊文献+

泌乳素瘤发病机制研究进展 被引量:6

Advance in Pathogenesis of Prolactinomas
下载PDF
导出
摘要 泌乳素瘤是最常见的具有内分泌功能的垂体瘤。对于泌乳素瘤的发病机制,目前认为可能与原癌基因和抑癌基因的改变及生长因子的变化有关。骨形态发生蛋白4(BMP-4)、视黄酸、过氧化物酶增殖物激活受体γ(PPAR-γ)、CCAAT增强子结合蛋白δ和神经调节蛋白1可能也参与了泌乳素瘤的发病。此外,肿瘤微环境在垂体肿瘤的发生中所起的作用也逐渐受到关注。但各种发病机制间的相互联系仍未明确,因此,泌乳素瘤发病机制的研究还应深入。 Prolactinoma is the most common type of secretory pituitary tumors. The pathogenesis of prolactinomas might be associated with the change of protooncogene,antioncogene,and growth factors. Recent studies have shown that bone morphogenetic protein 4( BMP-4),retinoic acid,peroxisome proliferator-activated receptor γ( PPAR-γ),neuregulin-1 and CCAAT enhancer binding protein δ( CEBPD) may also be involved in the pathogenesis of prolactinomas. Besides,microenvironment may play potential roles in the development of prolactinomas. However,the linkages among the various regulation pathways are not yet clear,further investigation of prolactinoma pathogenesis is urgently needed.
出处 《医学综述》 2016年第1期55-59,共5页 Medical Recapitulate
基金 国家自然科学基金(30900805 81370884)
关键词 泌乳素瘤 原癌基因 抑癌基因 生长因子 肿瘤微环境 Prolactinoma Protooncogene Antioncogene Growth factors Microenvironment
  • 相关文献

参考文献44

  • 1Daly AF,Rixhon M,Adam C,et al.High prevalence of pituitary adenomas:a cross-sectional study in the province of Liege,Belgium[J].J Clin Endocrinol Metab,2006,91(12):4769-4775.
  • 2Klibanski A.Clinical practice.Prolactinomas[J].N Engl J Med,2010,362(13):1219-1226.
  • 3Rostad S.Pituitary adenoma pathogenesis:an update[J].Curr Opin Endocrinol Diabetes Obes,2012,19(4):322-327.
  • 4Gadelha MR,Trivellin G,Hernández Ramírez LC,et al.Genetics of pituitary adenomas[J].Front Horm Res,2013,41:111-140.
  • 5Booth A,Trudeau T,Gomez C,et al.Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype[J].Mol Endocrinol,2014,28(12):1999-2011.
  • 6Melmed S.Pathogenesis of pituitary tumors[J].Nat Rev Endocrinol,2011,7(5):257-266.
  • 7Karga HJ,Alexander JM,Hedley-Whyte ET,et al.Ras mutations in human pituitary tumors[J].J Clin Endocrinol Metab,1992,74(4):914-919.
  • 8Pei L,Melmed S,Scheithauer B,et al.H-ras mutations in human pituitary carcinoma metastases[J].J Clin Endocrinol Metab,1994,78(4):842-846.
  • 9Cai WY,Alexander JM,Hedley-Whyte ET,et al.Ras mutations in human prolactinomas and pituitary carcinomas[J].J Clin Endocrinol Metab,1994,78(1):89-93.
  • 10Vallar L,Spada A,Giannattasio G.Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas[J].Nature,1987,330(6148):566-568.

二级参考文献27

  • 1Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab, 2004,89:1704-1711.
  • 2Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med, 2003,349: 2023-2033.
  • 3Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab,2001,86:3809-3814.
  • 4Mangupli R, Lisette A, Ivett C, et al. Improvement of acromegaly after octreotide LAR treatment. Pituitary, 2003,6: 29-34.
  • 5Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab, 2003, 88: 3090-3098.
  • 6Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab, 2003,88: 5258-5265.
  • 7Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab,2004,89:1577-1585.
  • 8Parkinson C, Kassem M, Heickendorff L, et al. Pegvisomant-induced serum insulin-like growth factor-Ⅰ normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab, 2003,88: 5650-5655.
  • 9Ferone D, Pivonello R, Lastoria S, et al. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinacmic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol, 2001,54:469-477.
  • 10Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab, 2004,89: 2452-2462.

共引文献16

同被引文献33

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部